Immunic, Inc. (IMUX) financial statements and ratios from SEC XBRL: revenue $1.04M (TTM), net margin -9343.5%, revenue growth -69.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.04M |
| Net Margin | -9343.5% |
| Revenue Growth (YoY) | -69.3% |
| EPS Growth (YoY) | -38.0% |
| FCF Growth (YoY) | 1.1% |
| Price / Book | 1.76 |
| Price / Sales | 69.77 |
| FCF Yield | -37.0% |
| Altman Z-Score | -6.07 (distress) |
| Sector P/E (Healthcare) | 21.7 |
IMUX overview · IMUX earnings · IMUX KPIs · IMUX investor relations · IMUX ownership · IMUX peers · IMUX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.